• Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease 

      Vesterhus, Mette; Nielsen, Mette; Hov, Johannes Espolin Roksund; Saffioti, Francesca; Manon-Jensen, Tina; Leeming, Diana Julie; Moum, Bjørn; Boberg, Kirsten Muri; Pinzani, Massimo; Karlsen, Tom Hemming; Karsdal, Morten A; Thorburn, Douglas (Journal article; Peer reviewed, 2021)
      Background & Aims: Primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) are phenotypically distinct autoimmune liver diseases that progress to cirrhosis and liver failure; ...
    • Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF 

      Fossdal, Guri; Mjelle, Anders Batman; Wiencke, Kristine; Bjørk, Ida Torunn; Gilja, Odd Helge; Folseraas, Trine; Karlsen, Tom Hemming; Rosenberg, William; Melvær, Giil Lasse; Vesterhus, Mette Nåmdal (Journal article; Peer reviewed, 2021)
      Background & Aims Primary sclerosing cholangitis (PSC) is a progressive liver disease characterised by fluctuating liver biochemistries and highly variable disease progression. The Enhanced Liver Fibrosis (ELF®) test and ...
    • Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis 

      Braadland, Peder Rustøen; Schneider, Kai Markus; Bergquist, Annika; Molinaro, Antonio; Lövgren-Sandblom, Anita; Henricsson, Marcus; Karlsen, Tom Hemming; Vesterhus, Mette Nåmdal; Trautwein, Christian; Hov, Johannes Espolin Roksund; Marschall, Hanns-Ulrich (Journal article; Peer reviewed, 2022)
      Background & Aims: Farnesoid X receptor (FXR) agonists and fibroblast growth factor 19 (FGF19) analogues suppress bile acid synthesis and are being investigated for their potential therapeutic efficacy in cholestatic liver ...